Clinical trial 2025-522058-38-00 · HER2 positive non-small cell lung cancer
Oncology research
12 Oct 2026
2025-522058-38-00 — is «authorised» on CTIS (EU Clinical Trials Information System).
Clinical trial 2025-522058-38-00 (phase II) is «authorised» on CTIS (EU Clinical Trials Information System).
Condition: HER2 positive non-small cell lung cancer · Registered interventions: Enhertu 100 mg powder for concentrate for solution for infusion · Recorded dates (source): 2026-10-09.
Source: https://euclinicaltrials.eu/ctis-public/view/2025-522058-38-00